Cell: Barrettinib reduces inflammation in rhesus monkeys infected with the new coronavirus

Nov 12, 2020 /---SARS-CoV-2-induced hypercytokinemia and inflammation are closely related to the severity of COVID-19 disease.
as a clinically approved JAK1/2 inhibitor, baricitinib is currently being studied in COVID-19 clinical trials.
a new study, researchers from Emory University in the United States studied the immunological and virological efficacy of Barrettinib in the sars-CoV-2-infected rhesus monkey model.
model simulates inflammatory characteristics observed in PATIENT-19 patients.
results were published online November 9, 2020 in the journal Cell under the title "Baricitinib treatment resolves lower airway macrophage and neutrophil search in SARS-CoV-2-infected rhesus macaques".
from Cell, 2020, doi:10.1016/j.cell.2020.11.007.
the virus shedding measured from nasal swabs, throat swabs, bronchopulmonal blisters and tissues did not decrease as a result of the use of barriteni.
, barrettinib inhibits the production of inflammatory cytokines in macrophages in the lungs.
type I IFN antiviral response and SARS-CoV-2 specific T-cell response were similar in two groups of rhesus monkeys treated with barriteni.
rhesus monkeys treated with barrettinib showed reduced inflammation, reduced inoculation of inflammatory cells in the lungs, reduced neural granulocyte capture network (NETosis) activity, and more limited lung pathology.
showed that in rhesus monkeys treated with barrettinib, the drug maintained a congenital antiviral response and a SARS-CoV-2-specific T-cell response.
importantly, rhesus monkeys treated with barriteni have a rapid and significant inhibitory effect on cytokines produced by macrophages in the lungs and on the cogeneration factors responsible for inflammation and neutral granulocyte recruitment.
data support the beneficial effects of barrettinib as a first-line treatment for inflammation caused by SARS-CoV-2 infection and shed light on the immunological mechanisms behind it.
(Bioon.com) Reference: Timothy N. Hoang et al. Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell, 2020, doi:10.1016/j.cell.2020.11.007.